
FEB 2 1 2007


1 200/	W.		U.S. I				PTO/SB/21 (09-04) hrough 07/31/2006. OMB 0651-0031 .S. DEPARTMENT OF COMMERCE	
Under the	duction Act of 1995.	no person	s are required to respond to a co Application Number	10/509,292	ormation u	nless it o	disolavs a valid OMB control number.	
TRANSMITTAL FORM		Filing Date	September	September 23, 2004 Drivas, D.				
		First Named Inventor	Drivas, D.					
		Art Unit	1644					
(to be used for all correspondence after initial filing)		Examiner Name	Crowder, C	, Chun				
Total Number of Pages in This Submission		Attorney Docket Number	MP-01	01				
ENCLOSURES (Check all that apply)								
		ENC	LOSURES (Check an	тат арріу,		After A	llowance Communication to TC	
Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request		Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence o	related Papers Convert to a al Application Attorney, Revocation f Correspondence Address Disclaimer for Refund		Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Response to Office Communication (1 page)Petition and Fee for Extension of Time (1 page; 2 copies)Return-receipt postcard			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
Firm Name Hoxie &	Tso LLP			,		-		
Signature	Signature A 1							
Printed name Arthur Yang								
Date February 14, 2007			Reg. No. 45,721					
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:								
Signature Millul Fanad								
Typed or printed name Michele Konrad						Date	February 14, 2007	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



DATE MAILED: 12/15/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



RECEIVED DEC 18 2006 HOXIE & TSO LLP



U.S. Patent and Tra mark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO. FILING DATE

FIRST NAMED INVENTOR / PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

EXAMINER					
CHUN	CROWDER				
ART UNIT	PAPER				
1644	20061202				

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed on 10/12/2006 is not fully responsive to the prior Office Action because of the following omissions or matters:

As part of this response to the restriction requirement mailed 09/07/2006, applicant has elected with traverse of Group I, drawn to a method for treating a subject, and species of SEQ ID NO:16 conjugated to DT. The traversal was on the ground that Jose et al. (JBC 1994, 179:881-887 Reference cited on IDS filed 01/03/05) do not teach human eotaxin and vaccines or immunogenic conjugates or methods of treatment involving generating an active immune response to eotaxin. This is not found persuasive for reasons of record. Further, it is noted that the instant claims are drawn to eotaxin in general and not to human eotaxin. Furthermore, Jose et al. teach that based on their study human eotaxin can be important in human asthmatic lung (see Results and Discussion on pages 883-886). Since Applicant's inventions do not contribute a special technical feature when viewed over the prior art they do not have a single general inventive concept and so lack unity of invention. Therefore, the Restriction Requirement is deemed proper and is made FINAL. Moreover, applicant has not indicated species of a specific condition as set forth in the Restriction Requirement mailed 09/07/2006 (see Section 9 on pages 4-5).

The restriction requirement indicated that is Group I is elected, applicant is further required to elect a method for treating specific condition (e.g. asthma as recited in claim 2).

As previously stated, applicant has not indicated the elected species of one specific condition.

Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chun Crowder whose telephone number is 571-272-8142. The examiner can normally be reached on 8:30-5:00. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor. Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

PHRUE CAMIDE PRINCES ON FERLICER PRINCES OF FERLICER

12/406

DTO 000 (Dev. 04.02

Information regarding the status of an apply ion may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published application, may be obtained from either Private PAIR or Fund PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Chun Crowder, Ph.D.

Patent Examiner

December 2, 2006